Latanoxam

Latanoprost, the active ingredient in Latanoxam, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure through increased uveoscleral outflow of aqueous humor and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients, and is well tolerated in most patients.

GNH USA supplies Latanoxam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Latanoxam (latanoprost) is used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Open‑angle glaucoma: reduces intra‑ocular pressure, thereby slowing progression of optic nerve damage and visual field loss. - Ocular hypertension: lowers elevated eye pressure, helping to prevent conversion to glaucoma and associated vision risk. - Pseudoexfoliative glaucoma: assists in controlling intra‑ocular pressure in this secondary open‑angle glaucoma subtype.

Latanoxam may cause ocular and systemic adverse reactions, which are categorized by frequency.

Common Side Effects: - Eye redness - Increased eyelash length - Darkening of the iris - Eye irritation or foreign body sensation

Serious or Rare Side Effects: - Uveitis (inflammation of the uvea) - Macular edema (fluid accumulation in the retina) - Severe allergic reaction (e.g., swelling, itching, or rash)

Before using Latanoxam, consider the following precautions to ensure safe and effective therapy.

- Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Contact lens wearers: remove lenses prior to instillation and wait at least 15 minutes before reinserting. - Concurrent ocular surgery: inform the surgeon of Latanoxam use. - Store at room temperature: keep the bottle in its original packaging, protect from light and moisture.

Latanoxam can interact with other ophthalmic or systemic agents; awareness of these interactions helps manage therapy.

Major Interactions (Avoid): - Use with systemic prostaglandin inhibitors may diminish Latanoxam’s IOP‑lowering effect. - Concurrent use with ocular prostaglandin analogs may cause additive pressure reduction and increase risk of hypotony.

Moderate Interactions (Monitor Closely): - Co‑administration with beta‑blocker eye drops may produce additive intra‑ocular pressure lowering. - Non‑steroidal anti‑inflammatory eye drops can increase ocular irritation. - Corticosteroid eye drops may counteract the pressure‑lowering effect of Latanoxam.